Axsome Therapeutics Inc. saw a significant price increase of 17.59%, crossing above the 5-day SMA, amidst a slight decline in the broader market with the Nasdaq-100 down 0.22% and the S&P 500 down 0.15%.
This surge is attributed to the FDA granting Priority Review for Axsome's supplemental NDA for AXS-05, with a target action date set for April 30, 2026. This expedited review process addresses the urgent medical needs of Alzheimer's patients experiencing agitation, potentially filling a critical market gap and enhancing Axsome's competitive position in the CNS sector.
The implications of this development are significant, as the approval of AXS-05 could lead to substantial revenue growth for Axsome, given the high demand for effective treatments in the Alzheimer's space. This move further solidifies Axsome's leadership in the biopharmaceutical industry.
Wall Street analysts forecast AXSM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AXSM is 196.82 USD with a low forecast of 148.00 USD and a high forecast of 248.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast AXSM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AXSM is 196.82 USD with a low forecast of 148.00 USD and a high forecast of 248.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 185.170
Low
148.00
Averages
196.82
High
248.00
Current: 185.170
Low
148.00
Averages
196.82
High
248.00
RBC Capital
Leonid Timashev
Outperform
maintain
$212 -> $219
2026-01-21
Reason
RBC Capital
Leonid Timashev
Price Target
$212 -> $219
AI Analysis
2026-01-21
maintain
Outperform
Reason
RBC Capital analyst Leonid Timashev raised the firm's price target on Axsome Therapeutics to $219 from $212 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies after meeting with managements.
H.C. Wainwright
H.C. Wainwright
Buy
upgrade
$200 -> $260
2026-01-20
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$200 -> $260
2026-01-20
upgrade
Buy
Reason
H.C. Wainwright raised the firm's price target on Axsome Therapeutics to $260 from $200 and keeps a Buy rating on the shares. The company's preliminary 2025 revenue numbers show commercial strength, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AXSM
Unlock Now
Piper Sandler
Overweight
upgrade
$148 -> $223
2026-01-16
Reason
Piper Sandler
Price Target
$148 -> $223
2026-01-16
upgrade
Overweight
Reason
Piper Sandler raised the firm's price target on Axsome Therapeutics to $223 from $148 and keeps an Overweight rating on the shares. The firm says it met with Axsome senior management recently, and gained more insights into commercial dynamics surrounding Auvelity in agitation associated with Alzheimer's disease. Given its view that a label expansion is highly likely, coupled with what in our view is strong visibility into continued brisk Auvelity growth in the major depressive disorder setting and the fact of a lengthy exclusivity runway into 2039, Piper is raising its price target.
Morgan Stanley
Overweight -> Equal Weight
downgrade
$196 -> $204
2026-01-08
Reason
Morgan Stanley
Price Target
$196 -> $204
2026-01-08
downgrade
Overweight -> Equal Weight
Reason
Morgan Stanley downgraded Axsome Therapeutics to Equal Weight from Overweight with a price target of $204, up from $196. Axsome announced on December 31 that the FDA accepted the AXS-05 sNDA for Alzheimer's Disease Agitation with Priority Review, immediately driving a sharp stock reaction, notes the analyst, who increased the firm's view of the probability of success for AXS05 in ADA to 85% from 75%. However, the post-event run-up has meaningfully reduced near-term upside from current levels, says the analyst, who views 2026 as "relatively catalyst-light" outside of the April-end PDUFA date for AXS-05 in ADA.
About AXSM
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
